セファクロル

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H334：吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P284：呼吸用保護具を着用すること。

  P304+P340：吸入した場合：空気の新鮮な場所に移し、呼吸しやすい 姿勢で休息させること。

  P342+P311：呼吸に関する症状が出た場合：医師に連絡すること。

セファクロル 価格

セファクロル 化学特性,用途語,生産方法

• 用途

  第 1 世代セフェム系抗生物質 です。細菌の細胞壁合成を阻害することによ り抗菌作用を示します。

• 効能

  抗生物質, 細胞壁合成阻害薬

• 商品名

  ケフラール (共和薬品工業); ケフラール (共和薬品工業); ケフラール (共和薬品工業); セファクロル (シオノケミカル); セファクロル (シオノケミカル); セファクロル (日医工); セファクロル (日医工); セファクロル (東和薬品); セファクロル (沢井製薬); セファクロル (沢井製薬); セファクロル (辰巳化学); セファクロル (長生堂製薬); セファクロル (長生堂製薬); トキクロル (コーアイセイ)

• 説明

  Cefaclor differs from cephalexin primarily in the bio-isosteric replacement of methyl by chlorine at C-3 and is quite acid stable, allowing oral administration. It also is quite stable to metabolism. It is less active against Gram-negative bacteria compared with the other second-generation cephalosporins but is more active against Gram-negative bacteria compared with the first-generation drugs.

• 化学的特性

  white crystalline solid

• 使用

  Cefaclor belongs to the family of antibiotics known as the cephalosporins (cefalosporins). The cephalosporins are broad-spectrum antibiotics that are used for the treatment of septicaemia, pneumonia, meningitis, biliary-tract infections, peritonitis, and

• 定義

  ChEBI: A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.

• 抗菌性

  It is less resistant than other group 2 cephalosporins to staphylococcal β-lactamase. It is active against N. gonorrhoeae and H. influenzae and against most enterobacteria, but it is susceptible to common enterobacterial β-lactamases. Pr. vulgaris and Providencia, Acinetobacter and Serratia spp. are resistant. B. fragilis and clostridia are resistant but other anaerobes are commonly susceptible.

• 臨床応用

  Cefaclor (Ceclor) is an orally active semisyntheticcephalosporin that was introduced in the American market in1979. It differs structurally from cephalexin in that the 3-methyl group has been replaced by a chlorine atom. It issynthesized from the corresponding 3-methylenecepham sulfoxideester by ozonolysis, followed by halogenation of theresulting β-ketoester. The 3-methylenecepham sulfoxideesters are prepared by rearrangement of the corresponding 6-acylaminopenicillanic acid derivative. Cefaclor is moderatelystable in acid and achieves enough oral absorption to provideeffective plasma levels (equal to about two-thirds of thoseobtained with cephalexin). The compound is apparentlyunstable in solution, since about 50% of its antimicrobial activityis lost in 2 hours in serum at 37°C. The antibacterialspectrum of activity is similar to that of cephalexin, but it isclaimed to be more potent against some species sensitiveto both agents. Currently, the drug is recommended for thetreatment of non–life-threatening infections caused by H.influenzae, particularly strains resistant to ampicillin.

• 副作用

  Apart from mild gastrointestinal disturbance, the drug is well tolerated. Transiently increased transaminase levels and symptomatic vaginal candidosis have been noted. Clusters of a serum sickness-like illness have been described in children.

• 安全性プロファイル

  Moderately toxic by intraperitoneal route. Human systemic effects by ingestion: joints, dermatitis, increased body temperature. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of Clí, SOx, an

セファクロル 上流と下流の製品情報

セファクロル 生産企業

Global(372)Suppliers

セファクロル スペクトルデータ(IR1、IR2、MS)

53994-73-3, セファクロル キーワード